HIV surrogate markers weighed.
作者信息
Cotton P
出版信息
JAMA. 1991 Mar 20;265(11):1357, 1361-2. doi: 10.1001/jama.265.11.1357.
PMID:1671883
Abstract
摘要
相似文献
1
HIV surrogate markers weighed.
JAMA. 1991 Mar 20;265(11):1357, 1361-2. doi: 10.1001/jama.265.11.1357.
2
Surrogate markers in AIDS: where are we? Where are we going?
Ann Intern Med. 1992 Apr 1;116(7):599-601. doi: 10.7326/0003-4819-116-7-599.
3
The fast track toward new AIDS drugs.
Nurse Pract Forum. 1991 Jun;2(2):80-1.
4
Surrogate markers in AIDS and cancer trials.
Stat Med. 1994;13(13-14):1423-35; discussion 1437-40. doi: 10.1002/sim.4780131318.
5
The utility of large, simple trials in the evaluation of AIDS treatment strategies.
Stat Med. 1994;13(5-7):405-15. doi: 10.1002/sim.4780130505.
6
[New, in Austria registered specialty drugs. Hivid (2',3'-dideoxycytidine; ddC)].[新的，在奥地利注册的专科药物。惠妥滋（2'，3'-双脱氧胞苷；ddC）]
Wien Klin Wochenschr. 1992;104(12):363-7.
7
Surrogate markers for AIDS treatment.
Nurs Times. 1991;87(22):49.
8
The AIDS epidemic and clinical trials.艾滋病流行与临床试验。
Acad Med. 1989 Nov;64(11):660-1. doi: 10.1097/00001888-198911000-00007.
9
Marker paths. MAP Workshop (Multi-cohort Analysis Project).标记路径。MAP 研讨会（多队列分析项目）。
Stat Med. 1993 Nov 30;12(22):2099-126.
10
Drug approval and AIDS: benefits for the elderly.
Health Aff (Millwood). 1990 Fall;9(3):123-30. doi: 10.1377/hlthaff.9.3.123.
引用本文的文献
1
Didanosine. A review of its antiviral activity, pharmacokinetic properties and therapeutic potential in human immunodeficiency virus infection.去羟肌苷。对其在人类免疫缺陷病毒感染中的抗病毒活性、药代动力学特性及治疗潜力的综述。
Drugs. 1992 Jul;44(1):94-116. doi: 10.2165/00003495-199244010-00008.
2
Zalcitabine. A review of its pharmacology and clinical potential in acquired immunodeficiency syndrome (AIDS).扎西他滨。对其在获得性免疫缺陷综合征（艾滋病）中的药理学及临床潜力的综述。
Drugs. 1992 Oct;44(4):656-83. doi: 10.2165/00003495-199244040-00009.
Zotero 插件